GlassScriptPhysician profile
Ze Zhang
NPI 1811239940
$44,057.06
in general payments reported to CMS, 2019-2025
23 companies · $6,661 in 2025
The $6,661 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $1,176 · 2021: $7,006 · 2022: $10K · 2023: $13K · 2024: $5,618 · 2025: $6,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Food and Beverage: $3,497 · Consulting Fee: $3,400 · Education: $42.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,090.00 |
| Food and Beverage | $3,497.13 |
| Consulting Fee | $3,400.00 |
| Education | $42.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $27,059.00 | 2021-2025 | Rhopressa, Rocklatan, Hydrus Microstent |
| Aerie Pharmaceuticals, INC. | $7,126.81 | 2019-2021 | |
| Sight Sciences, INC. | $5,174.55 | 2023-2024 | Omni Surgical System |
| Glaukos Corporation | $1,679.49 | 2019-2025 | Istent Trabecular Micro-Bypass Stent System, Idosetr, Idose |
| Abbvie INC. | $944.61 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Lumigan |
| Allergan, INC. | $915.38 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $317.20 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $123.61 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $116.20 | 2020 | |
| New World Medical,INC. | $101.55 | 2020-2023 | |
| Bausch & Lomb Americas INC. | $69.98 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $62.96 | 2019-2025 | |
| Dompe US, INC. | $60.87 | 2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $51.29 | 2019-2022 | |
| Biotissue Holdings INC. | $50.61 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $50.12 | 2024 | Vevye |
| Omeros Corporation | $31.57 | 2020 | |
| Merz North America, INC. | $30.00 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $22.84 | 2024 | Quatera 700 |
| Ocular Therapeutix, INC. | $19.26 | 2025 | Dextenza |
| Rayner Intraocular Lenses Limited | $18.20 | 2025 | Rayner Cataract Set 1, Rayone Spheric, Rayone Emv |
| Horizon Therapeutics Plc | $16.61 | 2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $14.35 | 2025 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ze Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.